Roles of LIM proteins in cardiac hypertrophy

Mei Han1, Jin-Kun Wen, Bin Zheng

  • 1Institute of Basic Medicine, Department of Biochemistry and Molecular Biology, Hebei Medical University, No. 361, Zhongshan East Road, Shijiazhuang 050017, China.

Future Cardiology
|October 7, 2009
PubMed

Insights

LIM proteins are crucial in cardiac hypertrophy, a condition causing significant human mortality. Understanding their function may lead to new therapies for managing this heart condition.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Cardiac hypertrophy is a major cause of human morbidity and mortality.
  • It results from conditions like hypertension and myocardial infarction.
  • Cardiac gene expression is regulated by transcription factors during hypertrophy.

Purpose of the Study:

  • To explore the role of LIM proteins in cardiac hypertrophy.
  • To understand the interactions and functions of LIM proteins in this condition.

Main Methods:

  • Review of scientific literature on LIM proteins and cardiac hypertrophy.
  • Analysis of protein domains and sequence homologies.
  • Investigation of LIM protein interactions with cytoskeletal and transcriptional machinery.

Main Results:

  • LIM proteins, including LIM-only proteins, muscle LIM protein, and human heart LIM protein, are involved in cardiac hypertrophy.
  • These proteins function as integrators of cytoskeletal assembly or coactivators in gene transcription.
  • Recent advancements highlight their complex roles and interactions in cardiac hypertrophy.

Conclusions:

  • LIM proteins play a significant role in the development of cardiac hypertrophy.
  • Further knowledge of LIM proteins offers potential for novel therapeutic strategies.
  • Understanding these proteins can improve the management of cardiac hypertrophy.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
416
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
343
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
752
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K